pharma · Advanced Systemic Mastocytosis · Systemic Mastocytosis
Blueprint Medicines
Blueprint Medicines (Netherlands) B.V.
Blueprint Medicines trial registry — 8 ClinicalTrials.gov studies with program phase, status, and indication context.
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2011
- Employees
- 741
- Programs
- 8
- Drugs
- 9
- Patents
- 0
Blueprint Medicines clinical trials
Registry index of 8 ClinicalTrials.gov studies linked to Blueprint Medicines programs — each row shows trial ID, program name, phase, status, and indication.
Blueprint Medicines trial registry — 8 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Blueprint Medicines.
-
BLU-285-3101 — Phase 2
Clinical update -
BLU-808-1201 — Phase 2
Clinical update -
BLU-285-2203 — Phase 2
Clinical update -
BLU-263-1201 — Phase 3
Clinical update -
avapritinib — Phase 3
Clinical update -
Elenestinib — Phase 3
Clinical update -
Avapritinib, Avapritinib — Approved
Clinical update -
AZACITIDINE — Phase 2
Clinical update